<unk>  is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. In 2006 the FDA expended approved use to include dermatofibrosarcoma protuberans (DFSP), myelodysplastic/myeloproliferative diseases (MDS/MPD), and aggressive systemic mastocytosis (ASM). Chronic myelogenous leukemia The U.S. Food and Drug Administration (FDA) has approved<unk>  as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed. Due in part to the development of<unk>  and related drugs, the five-year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009, to 70% in 2016. Starting from 2011, it became clear that CML patients have the same or almost the same life expectancy of the general population. Gastrointestinal stromal tumors The FDA first granted approval for advanced GIST patients in 2002. On 1 February 2012,<unk>  was approved for use after the surgical removal of KIT-positive tumors to help prevent recurrence. The drug is also approved in unresectable KIT-positive GISTs. Dermatofibrosarcoma protuberans (DFSP) The FDA granted approval for the treatment of dermatofibrosarcoma protuberans (DFSP) patients in 2006. Specifically adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). Prior to approval DFSP was considered unresponsive to chemotherapy treatments. Other The FDA has approved<unk>  for use in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements, aggressive systemic mastocytosis without or an unknown D816V c-KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (CHIC2 allele deletion) or FIP1L1-PDGFRα fusion kinase negative or unknown, unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. On 25 January 2013, Gleevec was approved for use in children with Ph+ ALL. For treatment of progressive plexiform neurofibromas associated with neurofibromatosis type I, early research has shown potential for using the c-KIT tyrosine kinase blocking properties of<unk> . According to a small trial,<unk>  is an effective drug in some patients with aggressive fibromatosis.
Imatinib
Neratinib
Dasatinib
Ponatinib
Afatinib
Tucatinib
Lapatinib
Fostamatinib